Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pacific Biosciences of California, Inc. - Common Stock (NQ:PACB)

1.310 +0.080 (+6.50%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pacific Biosciences of California, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
3 Russell 2000 Stocks Walking a Fine Line
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher... 
Via StockStory
PacBio (PACB) Shares Skyrocket, What You Need To Know
Shares of genomics company Pacific Biosciences of California (NASDAQ:PACB) jumped 10.4% in the afternoon session after it received favorable reviews from Wall Street, with analysts raising their price... 
Via StockStory
Topics Artificial Intelligence
The Analyst Verdict: Pacific Biosciences In The Eyes Of 4 Experts
 
Via Benzinga
Earnings Scheduled For August 7, 2025
 
Via Benzinga
Earnings Scheduled For May 8, 2025
 
Via Benzinga
PACB Q2 Deep Dive: International Demand, Consumables Growth, and Clinical Adoption Drive Results
Genomics company Pacific Biosciences of California (NASDAQ:PACB) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 10.4% year on year to $39.77 million. Its non-GAAP... 
Via StockStory
Topics World Trade
PacBio (PACB) Stock Trades Up, Here Is Why
Shares of genomics company Pacific Biosciences of California (NASDAQ:PACB) jumped 7.1% in the morning session after the company reported better-than-expected second-quarter 2025 financial results,... 
Via StockStory
PACB Sales Up 11%
Via The Motley Fool
PacBio (NASDAQ:PACB) Delivers Strong Q2 Numbers, Stock Soars
Genomics company Pacific Biosciences of California (NASDAQ:PACB) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 10.4% year on year to $39.77 million. Its non-GAAP... 
Via StockStory
Topics Artificial Intelligence
PacBio (PACB) Q2 Earnings Report Preview: What To Look For
Genomics company Pacific Biosciences of California (NASDAQ:PACB) will be announcing earnings results this Thursday afternoon. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence World Trade
PacBio, 10x Genomics, QuidelOrtho, STAAR Surgical, and Clover Health Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after industry bellwether UnitedHealth Group (UNH) slashed its 2025 profit forecast after reporting a significant surge in medical costs, sending... 
Via StockStory
3 Cash-Burning Stocks Walking a Fine Line
Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses risk dilution, mounting debt, or even... 
Via StockStory
Topics Bankruptcy
3 Low-Volatility Stocks We Steer Clear Of
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere. 
Via StockStory
Why PacBio (PACB) Stock Is Up Today
Shares of genomics company Pacific Biosciences of California (NASDAQ:PACB) jumped 7.4% in the afternoon session after the company announced it had joined the 1000 Genomes Long Read Sequencing Project,... 
Via StockStory
Topics Government World Trade
1 Healthcare Stock to Keep an Eye On and 2 to Be Wary Of
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of... 
Via StockStory
Topics Stocks
3 Unprofitable Stocks Walking a Fine Line
Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure. 
Via StockStory
Beyond The Numbers: 4 Analysts Discuss Pacific Biosciences Stock
 
Via Benzinga
3 Stocks Under $10 with Open Questions
Stocks under $10 pique our interest because they have room to grow (as well as the most affordable option contract premiums). That doesn’t mean they’re bargains though, and we urge investors to be... 
Via StockStory
The RealReal, Carnival, PacBio, Quest Resource, and Hudson Technologies Shares Are Soaring, What You Need To Know
A number of stocks jumped in the afternoon session after the major indices rebounded (Nasdaq +1.5%, S&P 500 +1.0%) as reports pointed to easing tensions between Israel and Iran. 
Via StockStory
Topics Artificial Intelligence Economy Stocks
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
PACB Q1 Earnings Call: Cost Reductions and Clinical Adoption Offset Market Headwinds
Genomics company Pacific Biosciences of California (NASDAQ:PACB) announced better-than-expected revenue in Q1 CY2025, but sales fell by 4.3% year on year to $37.15 million. Its non-GAAP loss of $0.15... 
Via StockStory
Topics World Trade
Q1 Earnings Roundup: PacBio (NASDAQ:PACB) And The Rest Of The Life Sciences Tools & Services Segment
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking at life sciences tools & services stocks,... 
Via StockStory
Topics Artificial Intelligence
3 Out-of-Favor Stocks Skating on Thin Ice
The past year hasn't been kind to the stocks featured in this article. Each has tumbled to their lowest points in 12 months, leaving investors to decide whether they're witnessing fire sales or falling... 
Via StockStory
Topics Supply Chain
Where Pacific Biosciences Stands With Analysts
 
Via Benzinga
1 Russell 2000 Stock with Exciting Potential and 2 to Approach with Caution
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the... 
Via StockStory
PacBio (NASDAQ:PACB) Beats Expectations in Strong Q1
Genomics company Pacific Biosciences of California (NASDAQ:PACB) reported Q1 CY2025 results beating Wall Street’s revenue expectations, but sales fell by 4.3% year on year to $37.15 million. Its... 
Via StockStory
PacBio (PACB) Q1 Earnings: What To Expect
Genomics company Pacific Biosciences of California (NASDAQ:PACB) will be reporting results tomorrow after market close. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
Cathie Wood Sells Palantir Shares Worth $2.65 Million Ahead Of Earnings, Doubles Down On This Chip Giant
On Wednesday, April 30, 2025, Cathie Wood sold $2.65 million worth of Palantir shares through various ARK ETFs. 
Via Benzinga
1 Volatile Stock to Target This Week and 2 to Keep Off Your Radar
Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains. This unpredictability can shake out even the most experienced... 
Via StockStory
Q4 Rundown: Illumina (NASDAQ:ILMN) Vs Other Life Sciences Tools & Services Stocks
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Illumina (NASDAQ:ILMN) and the... 
Via StockStory
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.